Anticancer agent 139

• Description:

  Anticancer agent 139 (Compound 6h) has potent anticancer activity. Anticancer agent 139 displayed a π–cationic interaction with the residue Lys352 of Tublin. Anticancer agent 139 has good anticancer activity against SNB-19, OVCAR-8, and NCI-H40 with PGIs of 86.61, 85.26, and 75.99, respectively. Anticancer agent 139 also has moderate anticancer activity against HOP-62, SNB-75, ACHN, NCI/ADR-RES, 786-O, A549/ATCC, HCT-116, and MDA-MB-231 with PGIs of 67.55, 65.46, 59.09, 59.02, 57.88, 56.88, 56.53, 56.4, and 51.88 respectively[1].

• UNSPSC:

  12352005

• Target:

  Microtubule/Tubulin

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Cytoskeleton

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/anticancer-agent-139.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC1=CC(C)=C(C=C1)NC2=NN=C(O2)C3=CC(F)=C(C(F)=C3)F

• Molecular Formula:

  C16H12F3N3O

• Molecular Weight:

  319.28

• References & Citations:

  [1]Mohit Agarwal, et al. Design, Synthesis, ADME, and Anticancer Studies of Newer N-Aryl-5- (3,4,5-Trifluorophenyl) -1,3,4-Oxadiazol-2-Amines: An Insight into Experimental and Theoretical Investigations. ACS Omega 2023, 8, 30, 26837-26849.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2954795-29-8]